Health Insurance (Pathology Services Table) Amendment Regulations 2003 (No. 1) (Cth)

Health Insurance (Pathology Services Table) Amendment Regulations 2003 (No. 1)1

Statutory Rules 2003 No. 702

I, PETER JOHN HOLLINGWORTH, Governor-General of the Commonwealth of Australia, acting with the advice of the Federal Executive Council, make the following Regulations under the Health Insurance Act 1973.

Dated 16 April 2003

PETER HOLLINGWORTH

Governor-General

By His Excellency’s Command

KAY PATTERSON

Minister for Health and Ageing

1Name of Regulations

 These Regulations are the Health Insurance (Pathology Services Table) Amendment Regulations 2003 (No. 1).

2Commencement

 These Regulations commence on 1 May 2003.

3Amendment of Health Insurance (Pathology Services Table) Regulations 2002

Schedule 1 amends the Health Insurance (Pathology Services Table) Regulations 2002.

Schedule 1Amendments

(regulation 3)

  

[1]Schedule 1, Part 2, subrules 13 (4) and (6)

omit

72817, 72823, 72824, 72825,

insert

72817, 72818, 72823, 72824, 72825, 72826,

[2]Schedule 1, Part 3, item 65117, paragraph (a)

omit

qualitative

[3]Schedule 1, Part 3, item 66650

omit

monitoring of gestational trophoblastic disease

insert

monitoring of gestational trophoblastic disease or a hepatic or germ cell tumour

[4]Schedule 1, Part 3, item 66740

omit

[5]Schedule 1, Part 3, item 66743

omit

item 66740

insert

item 66750 or 66751

[6]Schedule 1, Part 3, item 66746

omit

[7]Schedule 1, Part 3, after item 66749

insert

66750	Quantitation, in pregnancy, of any 2 of the following to detect foetal abnormality: (a) total human chorionic gonadotrophin (total HCG); (b) free alpha human chorionic gonadotrophin (free alpha HCG); (c) free beta human chorionic gonadotrophin (free beta HCG); (d) pregnancy associated plasma protein A (PAPP‑A);	39.25
(e) unconjugated oestriol (uE3); (f) alpha-fetoprotein (AFP); including (if performed) a service described in item 73527 or 73529 — 1 patient episode in a pregnancy
66751	Quantitation, in pregnancy, of any 3 or more tests described in item 66750	54.50

[8]Schedule 1, Part 3, item 69315, column 3

omit

64.00

insert

60.80

[9]Schedule 1, Part 3, item 69318, paragraph (a)

substitute

• (a)

  the detection of antigens (from any type of specimen) not elsewhere specified in this table, including item 69372; or

[10]Schedule 1, Part 3, items 69336 to 69345

substitute

69336	Microscopy of faeces for ova, cysts and parasites using concentration techniques and including the use of fixed stains for cryptosporidia and giardia — not more than 1 examination in a 7 day period	30.65
69339	Microscopy of faeces for ova, cysts and parasites using concentration techniques examined after examination described in item 69336 performed on a separately collected and identified specimen collected within 7 days of the examination described in item 69336 — not more than 1 examination in a 7 day period	18.65
69345	Culture and (if performed) microscopy without concentration techniques of faeces for faecal pathogens, using at least 2 selective or enrichment media and culture in at least 2 different atmospheres including (if performed): (a) pathogen identification and antibiotic susceptibility testing; and (b) the detection of clostridial toxins; and (c) a service described in item 69300 Not more than 1 examination in a 7 day period	51.65

[11]Schedule 1, Part 3, items 69348 and 69351

omit

[12]Schedule 1, Part 3, item 69363

omit

69348, 69351,

[13]Schedule 1, Part 3, item 69405, paragraph (a)

omit

hepatitis B surface antigen;

insert

carriage of hepatitis B;

[14]Schedule 1, Part 3, item 69408, paragraph (a)

omit

specific syphilis serology or, hepatitis B surface antigen;

insert

specific syphilis serology, carriage of hepatitis B;

[15]Schedule 1, Part 3, item 69411, paragraph (a)

omit

specific syphilis serology and Hepatitis B surface antigen;

insert

specific syphilis serology, carriage of hepatitis B;

[16]Schedule 1, Part 3, items 73287 and 73289

omit

or fragile X-site determination

[17]Schedule 1, Part 3, after item 73289

insert in Group P7 — Cytogenetics

73300	Detection of genetic mutation of the FMR1 gene by nucleic acid amplification (NAA) where: (a) the patient exhibits the specific clinical features of fragile X (A) syndrome, including intellectual disabilities; or (b) the patient has a first or second degree relative with a fragile X (A) mutation 1 or more tests	100.00
73305	Detection of genetic mutation of the FMR1 gene by Southern Blot, if the results of a service performed in item 73300 are inconclusive	200.00

[18]Schedule 1, Part 3, further amendments

 The following items are amended by omitting ‘69484,’:

 · item 69405, paragraph (b)

 · item 69408, paragraph (b)

 · item 69411, paragraph (b).

[19]Schedule 1, Part 4

omit

Alpha-fetoprotein AFP 66650–53, 66740–43

insert

Alpha-fetoprotein AFP 66650–53, 66743, 66750, 66751

[20]Schedule 1, Part 4

omit

Chorionic gonadotrophin — quantitation HCG 66650–53, 66740, 73529

insert

Chorionic gonadotrophin — quantitation HCG 66650–53, 66750, 66751, 73529

[21]Schedule 1, Part 4

omit

Down’s syndrome and neural tube defects NTDD 66740

insert

Down’s syndrome and neural tube defects NTDD 66750, 66751

[22]Schedule 1, Part 4

after

Follicle stimulating hormone (FSH) FSH 66695

insert

Fragile X FXS 73300, 73305

[23]Schedule 1, Part 4

omit

Hormones — human chorionic gonadotrophin — quantitation HCG 66650–53, 66740, 73529

insert

Hormones — human chorionic gonadotrophin — quantitation HCG 66650–53, 66750, 66751, 73529

[24]Schedule 1, Part 4

omit

Hormones — human placental lactogen HPL 66746

[25]Schedule 1, Part 4

omit

Hormones — oestriol E3 66740, 66746

insert

Hormones — oestriol E3 66750, 66751

[26]Schedule 1, Part 4

omit

Human chorionic gonadotrophin — quantitation HCG 66650–53, 66740, 73529

insert

Human chorionic gonadotrophin — quantitation HCG 66650–53, 66750, 66751, 73529

[27]Schedule 1, Part 4

omit

Human placental lactogen HPL 66746

[28]Schedule 1, Part 4

omit

Neural tube defects and Down’s syndrome NTDD 66740

insert

Neural tube defects and Down’s syndrome NTDD 66750, 66751

[29]Schedule 1, Part 4

omit

Oestriol E3 66740, 66746

insert

Oestriol E3 66750, 66751

[30]Schedule 1, Part 4

omit

Pregnancy testing — diagnosis of Down’s syndrome and neural tube defect NTDD 66740

insert

Pregnancy testing — diagnosis of Down’s syndrome and neural tube defect NTDD 66750, 66751

[31]Schedule 1, Part 4

omit

Protein, quantitation of — alpha fetoprotein AFP 66650–53, 66740, 66743

insert

Protein, quantitation of — alpha fetoprotein AFP 66650–53, 66743, 66750, 66751

[32]Schedule 1, Part 4

omit

Protein, quantitation of — for Down’s syndrome/neural tube defect testing NTDD 66740

insert

Protein, quantitation of — for Down’s syndrome/neural tube defect testing NTDD 66750, 66751

Notes

1. These Regulations amend Statutory Rules 2002 No. 245.

2. Notified in the Commonwealth of Australia Gazette